On 31 May, renowned philanthropist, Hong Kong Justice of the Peace, Chairman of the Environment and Conservation Fund Committee, former Chairman of Po Leung KUK of Hong Kong, Bauhinia Star, Medal of Honour recipient Dr Andrew Cheng, Fellow of the Royal College of Physicians of the United Kingdom and former Head of the Department of Clinical Oncology of the Chinese University of Hong Kong visited Shenzhen Cell Valley. Our chairman Shi Yuanyuan, deputy general manager Tang Xiaomeng, marketing minister Sun Rui, office director Luan Zhishi warm reception.


First of all, accompanied by Chairman Shi Yuanyuan, the visiting guests visited the smart exhibition hall, research and development laboratory, production and quality inspection workshop, etc., and initially understood the whole industry chain layout, development history, core team, production scale, research and development strength, quality management system and so on of Shenzhen Cell Valley in the field of cell and gene therapy.

At the symposium, Chairman Shi Yuanyuan expressed his sincere thanks to the visiting guests and introduced in detail the core innovative technologies and clinical treatment cases of Shenzhen Cell Valley, which has independent intellectual property rights. Chairman Shi Yuan said that the Cell Valley team adhering to the mission of "cells benefit all beings, genes create the future", with excellent research and development strength, the CAR T cells prepared under the strict production quality management system have benefited dozens of blood tumor patients, and provided many cell preparation for free. Recently, great progress has been made in the preparation of high-purity NK cells and CAR-NK cells, which provides technical possibility for breaking through many intractable chronic diseases such as solid tumors and Alzheimer's disease and Parkinson's disease.

Chairman Cheng spoke highly of the excellent efficacy of Shenzhen Cell Valley in immune cell clinical therapy and the concept of "cells benefit all beings", and said that the establishment of Shenzhen Cell Valley has provided an ideal platform for accelerating the clinical application of cutting-edge cell therapy technologies and reducing treatment costs. He hoped that through Hong Kong charity projects and relevant policies in Shenzhen and Hong Kong, While jointly promoting the development of cell therapy in the Guangdong-Hong Kong-Macao Greater Bay Area, the linkage between the Hong Kong Charity Foundation and Shenzhen Cell Valley and Shenzhen medical institutions has been established to provide a new guarantee mechanism for the exploration of cutting-edge cell immunotherapy for low-income cancer patients in Hong Kong. Dr. Shao Zude said that immune cell therapy provides a new treatment plan for diseases that cannot be solved by traditional medical methods, and has broad market prospects and social value. The Shenzhen-Hong Kong cooperation will deeply promote the integration and development of related technologies, and provide high-quality medical services for more cancer patients.

The two sides said that they will integrate their resources and fully cooperate to contribute to the charity of treating low-income cancer patients in Hong Kong.